STOCK TITAN

Kamada Ltd. - $KMDA STOCK NEWS

Welcome to our dedicated page for Kamada Ltd. news (Ticker: $KMDA), a resource for investors and traders seeking the latest updates and insights on Kamada Ltd. stock.

Kamada Ltd. (KMDA) is a leading biopharmaceutical company that specializes in plasma-derived protein therapeutics, targeting orphan indications. Utilizing its proprietary platform technology, Kamada excels in the extraction and purification of proteins from human plasma, producing highly-purified, liquid forms of alpha-1 antitrypsin (AAT) and other plasma-derived proteins. AAT is recognized for its immunomodulatory, anti-inflammatory, tissue-protective, and antimicrobial properties.

One of Kamada's flagship products is Glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration (FDA). Kamada markets Glassia in the U.S. through a strategic partnership with Baxter International. In addition to Glassia, Kamada offers a diverse product portfolio, including nine other pharmaceutical products distributed globally.

Kamada's robust late-stage product pipeline underscores its commitment to innovation in the specialty therapeutics market. The company operates through two primary segments: the Proprietary Products segment and the Distribution segment, with the majority of revenue derived from the Proprietary Products segment. Kamada's product categories encompass lung diseases, vaccines, hemophilia, immunoglobulins, critical care, and diagnostics.

Recently, Kamada announced a significant development in its strategic partnership with Kedrion Biopharma. The companies have executed a binding memorandum of understanding for an 8-year extension of the KEDRAB® US distribution agreement, starting January 2024. This agreement includes potential expansion of Kedrion's distribution of KEDRAB® beyond the U.S. and collaboration on expanding Kedrion products' distribution in Israel.

KEDRAB® is a Human Rabies Immune Globulin (HRIG) used for passive, transient post-exposure prophylaxis (PEP) of rabies infection, approved by the FDA in August 2017. The agreement signifies a significant milestone for Kamada, maximizing the future growth and value potential of this important product. Kamada continues to prioritize patient care and remains a pivotal player in the plasma-derived therapies sector.

Rhea-AI Summary

Kamada reported strong first quarter 2024 financial results with a 23% increase in revenues and a 96% rise in profitability. The company's top-line growth was driven by U.S. sales of KEDRAB® and CYTOGAM®. Kamada increased its full-year revenue guidance to $158-162 million and adjusted EBITDA to $28-32 million. The company remains optimistic about its growth prospects beyond 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.32%
Tags
-
Rhea-AI Summary

Kamada will announce its first quarter 2024 financial results on May 8, 2024, before the U.S. financial markets open. The company, known for its rare condition treatments, will host an investment community conference call to discuss the results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.87%
Tags
-
Rhea-AI Summary
Kamada Ltd. reports successful financial results for 2023, with total revenues of $142.5 million and adjusted EBITDA of $24.1 million, representing margins of 17%. The company expects further growth in 2024, with revenue guidance of $156-160 million and adjusted EBITDA guidance of $27-30 million. Key drivers include increased sales of KEDRAB anti-rabies immunoglobulin and promotion of CYTOGAM. The extended distribution agreement with Kedrion guarantees significant revenues, with $180 million expected in the first four years. Kamada's U.S. team is making progress in promoting their portfolio, including CYTOGAM and VARIZIG. The company continues to expand internationally, focusing on territories like Canada, Asia, Latin America, and the Middle East.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.02%
Tags
none
Rhea-AI Summary
Kamada Ltd. (KMDA) reports record annual revenues of $142.5 million for fiscal year 2023, a 10% increase from 2022. Adjusted EBITDA was $24.1 million, up 35% year-over-year. The company expects double-digit growth in fiscal year 2024 with anticipated revenues of $156-160 million and adjusted EBITDA of $27-30 million. Kamada also announced an extended U.S. distribution agreement with Kedrion for KEDRAB® with $180 million in revenues over four years. Positive FDA feedback on Phase 3 AAT clinical trial was received. Financially, total revenues grew, but net income for 2023 was $8.3 million compared to a loss in 2022. Cash provided by operating activities decreased to $4.3 million from $28.6 million in the prior year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.02%
Tags
-
Rhea-AI Summary
Kamada Ltd. to Release Q4 and FY2023 Financial Results and 2024 Guidance, Hosts Conference Call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
-
Rhea-AI Summary
Kedrion Biopharma (KEDR) extends US distribution agreement for KEDRAB® with Kamada Ltd. (KMDA) until 2032, with potential expansion into new territories. The agreement aims to combat Rabies, a global public health concern causing 59,000 human deaths annually. Kedrion confirms its commitment to fighting Rabies and other serious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
none
Rhea-AI Summary
Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) has announced a binding memorandum of understanding with Kedrion for the amendment and extension of the KEDRAB® U.S. distribution agreement. The agreement includes $180 million of revenues to Kamada over the first four years of the eight-year term, reflecting KEDRAB®'s significant U.S. market share and continued growth. There is also potential expansion of KEDRAB distribution by Kedrion to other territories beyond the U.S. This is Kamada's largest commercial agreement to date, maximizing the future growth and value potential of this important product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.87%
Tags
none
-
Rhea-AI Summary
Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) reported Q3 2023 revenues of $37.9 million, an 18% YoY increase, and adjusted EBITDA of $7.9 million, a 31% YoY increase. Nine-month 2023 revenues were $106.1 million, up 26% YoY, with adjusted EBITDA of $17.7 million, a 67% YoY increase. Positive outlook for Q4 supports reiteration of FY 2023 revenue guidance of $138-146 million and adjusted EBITDA of $22-26 million. Recent achievements include CYTOGAM® milestones and a $60 million private placement with FIMI Opportunity Funds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
none
-
Rhea-AI Summary
Kamada Ltd. (NASDAQ & TASE: KMDA) to release financial results for the third quarter and first nine months ended September 30, 2023. An investment community conference call will be held on November 13, 2023, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and interested parties may participate by dialing 1-877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel) or 1 201-689-8263 (International) using conference ID 13741701. Webcast available at: https://viavid.webcasts.com/starthere.jsp?ei=1637192&tp_key=fd85a910fe. The call will be archived for 90 days on the Company’s website at www.kamada.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
Rhea-AI Summary
Kamada Ltd. assures business continuity despite evolving circumstances in Israel
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
none

FAQ

What does Kamada Ltd. specialize in?

Kamada Ltd. specializes in plasma-derived protein therapeutics for orphan indications, utilizing proprietary technology for protein extraction and purification.

What is Kamada's flagship product?

Kamada's flagship product is Glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived alpha-1 antitrypsin (AAT) product approved by the U.S. FDA.

Who are Kamada's strategic partners?

Kamada has strategic partnerships with Baxter International for the U.S. marketing of Glassia® and with Kedrion Biopharma for the distribution of KEDRAB® in the U.S.

What are the main product categories of Kamada?

Kamada's product categories include lung diseases, vaccines, hemophilia, immunoglobulins, critical care, and diagnostics.

What recent agreement has Kamada announced?

Kamada recently announced an 8-year extension of its KEDRAB® US distribution agreement with Kedrion Biopharma, starting January 2024.

What is KEDRAB®?

KEDRAB® is a Human Rabies Immune Globulin (HRIG) used for passive, transient post-exposure prophylaxis of rabies infection, approved by the FDA in August 2017.

How does Kamada derive its majority of revenue?

Kamada derives the majority of its revenue from its Proprietary Products segment.

What are the key properties of alpha-1 antitrypsin (AAT)?

Alpha-1 antitrypsin (AAT) has immunomodulatory, anti-inflammatory, tissue-protective, and antimicrobial properties.

Which markets does Kamada distribute its pharmaceutical products?

Kamada markets its pharmaceutical products globally through strategic partnerships and distributors.

What is the significance of Kamada's recent agreement with Kedrion Biopharma?

The agreement with Kedrion Biopharma signifies a major milestone, potentially expanding Kedrion's distribution of KEDRAB® beyond the U.S. and enhancing Kamada's growth potential.

Kamada Ltd.

Nasdaq:KMDA

KMDA Rankings

KMDA Stock Data

293.15M
8.71M
7.32%
49.4%
0.07%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Rehovot

About KMDA

kamada ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. the company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce alpha-1 antitrypsin (aat) in a highly-purified, liquid form, as well as other plasma-derived proteins. aat is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. the company’s flagship product is glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived aat product approved by the u.s. food and drug administration. kamada markets glassia in the u.s. through a strategic partnership with baxter international. in addition to glassia, kamada has a product line of nine other pharmaceutical products that are marketed through distributor